- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
InSite teams with IBM for data center
Xoft prepares brachytherapy product for Canada
InSite teams with IBM for data center
InSite One is purchasing IBM storage and servers for its primary data center in Connecticut. Over the next three to five years, the company expects to replace and expand its existing storage and servers there to more than 1 petabyte. IBM will supply IBM System x Servers and DS3200 Storage systems. The total value of the agreement is pegged at more than $15 million. The two companies will also collaborate on client enterprise storage and archiving opportunities in which InSite One sells services and IBM sells storage and infrastructure solutions.
Xoft prepares brachytherapy product for Canada
Regulators in Canada have granted a medical device license for the sale in that country of Xoft's Axxent Electronic Brachytherapy System. The system delivers localized, nonradioactive, isotope-free radiation treatment in minimally shielded clinical settings. It has been commercially available in the U.S. since 2006 under an FDA clearance for the treatment of early stage breast cancer, endometrial cancer, and skin and surface indications.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
